<p>PROCEPT BioRobotics（纳斯达克股票代码：PRCT - 获取免费报告）在周四发布的报告中，Truist Financial 的股票研究人员将其目标价格从 50.00 美元下调至 47.00 美元，Benzinga 报道。该公司目前对该股票的评级为 “买入”。Truist Financial 的目标价格表明，与该股票之前的收盘价相比，存在 38.43% 的潜在上涨空间。</p>
<p>获取 <strong>PROCEPT BioRobotics</strong> 的提醒：</p>
<ul>
<li>3 只被低估的机器人股票，准备迎来巨额收益</li>
</ul>
<p>其他几家研究公司也对 PRCT 发布了报告。美国银行在 12 月 8 日的研究报告中重申了 “中性” 评级，并将 PROCEPT BioRobotics 的目标价格设定为 38.00 美元（从 55.00 美元下调）。摩根士丹利在 12 月 2 日的研究报告中将 PROCEPT BioRobotics 的目标价格从 56.00 美元下调至 51.00 美元，并对该股票给予 “增持” 评级。派珀·桑德勒在 11 月 5 日的报告中重申了 “增持” 评级，并将 PROCEPT BioRobotics 的目标价格设定为 50.00 美元（从 55.00 美元下调）。BTIG 研究在 9 月 16 日的研究报告中重申了 PROCEPT BioRobotics 的 “中性” 评级。最后，Weiss Ratings 在 10 月 8 日的研究报告中重申了 PROCEPT BioRobotics 的 “卖出（e+）” 评级。一位股票研究分析师对该股票给予了强烈买入评级，九位分析师给予买入评级，两位分析师给予持有评级，一位分析师给予卖出评级。根据 MarketBeat 的数据，该公司的平均评级为 “适度买入”，平均目标价格为 53.40 美元。</p>
<p><strong>查看我们对 PRCT 的最新股票分析</strong></p>
<h2>PROCEPT BioRobotics 股票表现</h2>
<ul>
<li>PROCEPT BioRobotics 是外科机器人领域的下一个大事件吗？</li>
</ul>
<p>在周四的交易中，PROCEPT BioRobotics 的股票上涨了 0.17 美元，达到 33.95 美元。该公司 132,850 股股票被交易，交易量低于其平均交易量 1,116,144 股。该公司的 50 日简单移动平均线为 33.03 美元，200 日简单移动平均线为 43.01 美元。该股票的市值为 19 亿美元，市盈率为-22.15，贝塔值为 0.99。PROCEPT BioRobotics 的 52 周低点为 27.80 美元，52 周高点为 89.49 美元。该公司的债务与股本比率为 0.14，速动比率为 7.20，流动比率为 8.44。</p>
<p>PROCEPT BioRobotics（纳斯达克股票代码：PRCT - 获取免费报告）在 11 月 4 日最后发布了其财报。该公司报告本季度每股收益为（0.38 美元），超过分析师一致预期的（0.41 美元）0.03 美元。PROCEPT BioRobotics 的股本回报率为-21.72%，净利润率为-28.20%。该公司本季度的收入为 8333 万美元，而一致预期为 8078 万美元。在去年同期，该公司每股收益为（0.40 美元）。与去年同期相比，该公司的收入增长了 42.6%。研究分析师平均预测 PROCEPT BioRobotics 在本年度将发布-1.75 美元的每股收益。</p>
<h2>机构投资者对 PROCEPT BioRobotics 的看法</h2>
<ul>
<li>为什么 Intuitive Surgical 的股票在医疗领域占据主导地位</li>
</ul>
<p>几家机构投资者和对冲基金最近增加或减少了在 PRCT 的持股。JTC Employer Solutions Trustee Ltd 在第三季度收购了 PROCEPT BioRobotics 的新股份，价值约 30,000 美元。BI Asset Management Fondsmaeglerselskab A S 在第一季度收购了 PROCEPT BioRobotics 的新头寸，价值约 40,000 美元。Vega Investment Solutions 在第二季度将其在 PROCEPT BioRobotics 的持股增加了 52.0%。Vega Investment Solutions 现在拥有 775 股该公司的股票，价值 45,000 美元，此前在上个季度又收购了 265 股。US Bancorp DE 在第三季度将其在 PROCEPT BioRobotics 的持股增加了 175.7%。US Bancorp DE 现在拥有 1693 股该公司的股票，价值 60,000 美元，此前在上个季度又收购了 1079 股。最后，AlphaQuest LLC 在第二季度将其在 PROCEPT BioRobotics 的持股增加了 1262.5%。AlphaQuest LLC 现在拥有 1090 股该公司的股票，价值 63,000 美元，此前在上个季度又购买了 1010 股。机构投资者和对冲基金持有该公司 89.46% 的股票。</p>
<h2>PROCEPT BioRobotics 公司简介</h2>
<p>（获取免费报告）</p>
<p>PROCEPT BioRobotics 公司是一家外科机器人公司，专注于在美国和国际上开发泌尿科的变革性解决方案。该公司开发、制造和销售 AquaBeam 机器人系统，这是一种图像引导的外科机器人系统，旨在用于微创泌尿外科手术，重点治疗良性前列腺增生（BPH）。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 PROCEPT BioRobotics</li>
<li>股票分红削减发生，你准备好了吗？</li>
<li>3 只便宜的分红股票，可以战胜通货膨胀并支付你等待的费用</li>
<li>如何找到可以投资和交易的便士股票</li>
<li>3 只可能在 2026 年扭转局面的新年决议股票</li>
<li>最活跃的股票：美元交易量与股票交易量</li>
<li>大麻股票反弹：梦想还是机会？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJDVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJDVA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 PROCEPT BioRobotics 吗？</h2>
<p>在你考虑 PROCEPT BioRobotics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 PROCEPT BioRobotics 并不在名单上。</p>
<p>虽然 PROCEPT BioRobotics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

PRCT

<p>Truist Financial 已将 PROCEPT BioRobotics 的目标价从 50.00 美元下调至 47.00 美元，维持 “买入” 评级。修订后的目标价表明相较于前一交易日收盘价有 38.43% 的潜在上涨空间。其他公司也调整了他们的评级和目标，观点各异，从 “中性” 到 “增持” 不等。该股票的表现和财务指标得到了强调，机构投资者表现出显著的兴趣</p>

<p>PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) had its price objective decreased by equities researchers at Truist Financial from $50.00 to $47.00 in a report issued on Thursday,Benzinga reports. The firm currently has a &#34;buy&#34; rating on the stock. Truist Financial's target price indicates a potential upside of 38.43% from the stock's previous close.</p>
<div class="lb-trans"><p>PROCEPT BioRobotics（纳斯达克股票代码：PRCT - 获取免费报告）在周四发布的报告中，Truist Financial 的股票研究人员将其目标价格从 50.00 美元下调至 47.00 美元，Benzinga 报道。该公司目前对该股票的评级为 “买入”。Truist Financial 的目标价格表明，与该股票之前的收盘价相比，存在 38.43% 的潜在上涨空间。</p>
</div><p>Get <strong>PROCEPT BioRobotics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>PROCEPT BioRobotics</strong> 的提醒：</p>
</div><ul>
<li>3 Underrated Robotics Stocks Poised for Huge Gains</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只被低估的机器人股票，准备迎来巨额收益</li>
</ul>
</div><p>Several other research firms have also issued reports on PRCT. Bank of America reissued a &#34;neutral&#34; rating and set a $38.00 target price (down from $55.00) on shares of PROCEPT BioRobotics in a research note on Monday, December 8th. Morgan Stanley lowered their price target on PROCEPT BioRobotics from $56.00 to $51.00 and set an &#34;overweight&#34; rating on the stock in a research report on Tuesday, December 2nd. Piper Sandler reissued an &#34;overweight&#34; rating and issued a $50.00 price objective (down from $55.00) on shares of PROCEPT BioRobotics in a report on Wednesday, November 5th. BTIG Research reaffirmed a &#34;neutral&#34; rating on shares of PROCEPT BioRobotics in a research note on Tuesday, September 16th. Finally, Weiss Ratings reiterated a &#34;sell (e+)&#34; rating on shares of PROCEPT BioRobotics in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $53.40.</p>
<div class="lb-trans"><p>其他几家研究公司也对 PRCT 发布了报告。美国银行在 12 月 8 日的研究报告中重申了 “中性” 评级，并将 PROCEPT BioRobotics 的目标价格设定为 38.00 美元（从 55.00 美元下调）。摩根士丹利在 12 月 2 日的研究报告中将 PROCEPT BioRobotics 的目标价格从 56.00 美元下调至 51.00 美元，并对该股票给予 “增持” 评级。派珀·桑德勒在 11 月 5 日的报告中重申了 “增持” 评级，并将 PROCEPT BioRobotics 的目标价格设定为 50.00 美元（从 55.00 美元下调）。BTIG 研究在 9 月 16 日的研究报告中重申了 PROCEPT BioRobotics 的 “中性” 评级。最后，Weiss Ratings 在 10 月 8 日的研究报告中重申了 PROCEPT BioRobotics 的 “卖出（e+）” 评级。一位股票研究分析师对该股票给予了强烈买入评级，九位分析师给予买入评级，两位分析师给予持有评级，一位分析师给予卖出评级。根据 MarketBeat 的数据，该公司的平均评级为 “适度买入”，平均目标价格为 53.40 美元。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on PRCT</strong></p>
<div class="lb-trans"><p><strong>查看我们对 PRCT 的最新股票分析</strong></p>
</div><h2>PROCEPT BioRobotics Stock Performance</h2>
<div class="lb-trans"><h2>PROCEPT BioRobotics 股票表现</h2>
</div><ul>
<li>Is PROCEPT BioRobotics the Next Big Thing in Surgical Robotics?</li>
</ul>
<div class="lb-trans"><ul>
<li>PROCEPT BioRobotics 是外科机器人领域的下一个大事件吗？</li>
</ul>
</div><p>Shares of PROCEPT BioRobotics stock traded up $0.17 during trading on Thursday, hitting $33.95. 132,850 shares of the company's stock were exchanged, compared to its average volume of 1,116,144. The business has a 50-day simple moving average of $33.03 and a 200-day simple moving average of $43.01. The stock has a market capitalization of $1.90 billion, a price-to-earnings ratio of -22.15 and a beta of 0.99. PROCEPT BioRobotics has a 52-week low of $27.80 and a 52-week high of $89.49. The company has a debt-to-equity ratio of 0.14, a quick ratio of 7.20 and a current ratio of 8.44.</p>
<div class="lb-trans"><p>在周四的交易中，PROCEPT BioRobotics 的股票上涨了 0.17 美元，达到 33.95 美元。该公司 132,850 股股票被交易，交易量低于其平均交易量 1,116,144 股。该公司的 50 日简单移动平均线为 33.03 美元，200 日简单移动平均线为 43.01 美元。该股票的市值为 19 亿美元，市盈率为-22.15，贝塔值为 0.99。PROCEPT BioRobotics 的 52 周低点为 27.80 美元，52 周高点为 89.49 美元。该公司的债务与股本比率为 0.14，速动比率为 7.20，流动比率为 8.44。</p>
</div><p>PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last issued its earnings results on Tuesday, November 4th. The company reported ($0.38) EPS for the quarter, topping analysts' consensus estimates of ($0.41) by $0.03. PROCEPT BioRobotics had a negative return on equity of 21.72% and a negative net margin of 28.20%.The firm had revenue of $83.33 million for the quarter, compared to the consensus estimate of $80.78 million. During the same quarter in the prior year, the business earned ($0.40) earnings per share. The company's revenue was up 42.6% compared to the same quarter last year. On average, research analysts forecast that PROCEPT BioRobotics will post -1.75 EPS for the current year.</p>
<div class="lb-trans"><p>PROCEPT BioRobotics（纳斯达克股票代码：PRCT - 获取免费报告）在 11 月 4 日最后发布了其财报。该公司报告本季度每股收益为（0.38 美元），超过分析师一致预期的（0.41 美元）0.03 美元。PROCEPT BioRobotics 的股本回报率为-21.72%，净利润率为-28.20%。该公司本季度的收入为 8333 万美元，而一致预期为 8078 万美元。在去年同期，该公司每股收益为（0.40 美元）。与去年同期相比，该公司的收入增长了 42.6%。研究分析师平均预测 PROCEPT BioRobotics 在本年度将发布-1.75 美元的每股收益。</p>
</div><h2>Institutional Investors Weigh In On PROCEPT BioRobotics</h2>
<div class="lb-trans"><h2>机构投资者对 PROCEPT BioRobotics 的看法</h2>
</div><ul>
<li>Why Intuitive Surgical Stock is Dominating the Medical Sector</li>
</ul>
<div class="lb-trans"><ul>
<li>为什么 Intuitive Surgical 的股票在医疗领域占据主导地位</li>
</ul>
</div><p>Several institutional investors and hedge funds have recently added to or reduced their stakes in PRCT. JTC Employer Solutions Trustee Ltd acquired a new stake in shares of PROCEPT BioRobotics in the third quarter valued at about $30,000. BI Asset Management Fondsmaeglerselskab A S acquired a new position in PROCEPT BioRobotics during the first quarter worth about $40,000. Vega Investment Solutions grew its stake in PROCEPT BioRobotics by 52.0% during the 2nd quarter. Vega Investment Solutions now owns 775 shares of the company's stock valued at $45,000 after acquiring an additional 265 shares in the last quarter. US Bancorp DE raised its holdings in PROCEPT BioRobotics by 175.7% in the 3rd quarter. US Bancorp DE now owns 1,693 shares of the company's stock valued at $60,000 after acquiring an additional 1,079 shares during the last quarter. Finally, AlphaQuest LLC lifted its stake in PROCEPT BioRobotics by 1,262.5% in the 2nd quarter. AlphaQuest LLC now owns 1,090 shares of the company's stock worth $63,000 after purchasing an additional 1,010 shares in the last quarter. Institutional investors and hedge funds own 89.46% of the company's stock.</p>
<div class="lb-trans"><p>几家机构投资者和对冲基金最近增加或减少了在 PRCT 的持股。JTC Employer Solutions Trustee Ltd 在第三季度收购了 PROCEPT BioRobotics 的新股份，价值约 30,000 美元。BI Asset Management Fondsmaeglerselskab A S 在第一季度收购了 PROCEPT BioRobotics 的新头寸，价值约 40,000 美元。Vega Investment Solutions 在第二季度将其在 PROCEPT BioRobotics 的持股增加了 52.0%。Vega Investment Solutions 现在拥有 775 股该公司的股票，价值 45,000 美元，此前在上个季度又收购了 265 股。US Bancorp DE 在第三季度将其在 PROCEPT BioRobotics 的持股增加了 175.7%。US Bancorp DE 现在拥有 1693 股该公司的股票，价值 60,000 美元，此前在上个季度又收购了 1079 股。最后，AlphaQuest LLC 在第二季度将其在 PROCEPT BioRobotics 的持股增加了 1262.5%。AlphaQuest LLC 现在拥有 1090 股该公司的股票，价值 63,000 美元，此前在上个季度又购买了 1010 股。机构投资者和对冲基金持有该公司 89.46% 的股票。</p>
</div><h2>PROCEPT BioRobotics Company Profile</h2>
<div class="lb-trans"><h2>PROCEPT BioRobotics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).</p>
<div class="lb-trans"><p>PROCEPT BioRobotics 公司是一家外科机器人公司，专注于在美国和国际上开发泌尿科的变革性解决方案。该公司开发、制造和销售 AquaBeam 机器人系统，这是一种图像引导的外科机器人系统，旨在用于微创泌尿外科手术，重点治疗良性前列腺增生（BPH）。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than PROCEPT BioRobotics</li>
<li>Stock Dividend Cuts Happen Are You Ready?</li>
<li>3 Cheap Dividend Stocks That Can Beat Inflation and Pay You to Wait</li>
<li>How to find penny stocks to invest and trade</li>
<li>3 New Year’s Resolution Stocks That Could Turn Around in 2026</li>
<li>Most active stocks: Dollar volume vs share volume</li>
<li>Cannabis Stocks Up for Reversal: Pipedreams or Opportunity?</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 PROCEPT BioRobotics</li>
<li>股票分红削减发生，你准备好了吗？</li>
<li>3 只便宜的分红股票，可以战胜通货膨胀并支付你等待的费用</li>
<li>如何找到可以投资和交易的便士股票</li>
<li>3 只可能在 2026 年扭转局面的新年决议股票</li>
<li>最活跃的股票：美元交易量与股票交易量</li>
<li>大麻股票反弹：梦想还是机会？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJDVA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=PRCT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in PROCEPT BioRobotics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 PROCEPT BioRobotics 吗？</h2>
</div><p>Before you consider PROCEPT BioRobotics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 PROCEPT BioRobotics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PROCEPT BioRobotics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 PROCEPT BioRobotics 并不在名单上。</p>
</div><p>While PROCEPT BioRobotics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 PROCEPT BioRobotics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Truist Financial 已下调对 PROCEPT BioRobotics（NASDAQ:PRCT）股票价格的预期